Theresa E. Hickey

1st Floor Maternity Building, 28 Woodville Road
Woodville, SA 5011, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 15, 2025

Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.

Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.

Journal: European urology focus

Published: February 02, 2025

A Deep Learning Approach for the Classification of Fibroglandular Breast Density in Histology Images of Human Breast Tissue.

A Deep Learning Approach for the Classification of Fibroglandular Breast Density in Histology Images of Human Breast Tissue.

Journal: Cancers

Published: December 13, 2024

Steroid receptors in hormone dependent or sensitive cancers: The field of play now and looking forward.

Steroid receptors in hormone dependent or sensitive cancers: The field of play now and looking forward.

Journal: The Journal of steroid biochemistry and molecular biology

Published: November 14, 2024

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.

Journal: The Lancet. Oncology

Published: October 13, 2023

Designing Fluorescent Nuclear Permeable Peptidomimetics to Target Proliferating Cell Nuclear Antigen.

Designing Fluorescent Nuclear Permeable Peptidomimetics to Target Proliferating Cell Nuclear Antigen.

Journal: Journal of medicinal chemistry

Published: July 25, 2023

Library size confounds biology in spatial transcriptomics data.

Library size confounds biology in spatial transcriptomics data.

Journal: Genome biology

Published: July 12, 2023

Selective inhibition of CDK9 in triple negative breast cancer.

Selective inhibition of CDK9 in triple negative breast cancer.

Journal: Oncogene

Published: March 24, 2023

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

Journal: EMBO molecular medicine

Published: March 21, 2023

The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer.

The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer.

Journal: Genome biology

Published: March 02, 2023

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.

Journal: Nature structural & molecular biology

Published: December 13, 2022

The molecular consequences of androgen activity in the human breast.

The molecular consequences of androgen activity in the human breast.

Journal: Cell genomics

Published: August 01, 2022

Showing 1-12 of 59

Last Updated: 09/26/2026